바로가기메뉴

본문 바로가기 주메뉴 바로가기

ACOMS+ 및 학술지 리포지터리 설명회

  • 한국과학기술정보연구원(KISTI) 서울분원 대회의실(별관 3층)
  • 2024년 07월 03일(수) 13:30
 

Journal of the Korean Association of Oral and Maxillofacial Surgeons

  • P-ISSN2234-7550
  • E-ISSN2234-5930
  • SCOPUS, KCI, ESCI

Osteonecrosis of the jaw in the era of targeted therapy and immunotherapy in oncology

Journal of the Korean Association of Oral and Maxillofacial Surgeons / Journal of the Korean Association of Oral and Maxillofacial Surgeons, (P)2234-7550; (E)2234-5930
2019, v.45 no.1, pp.3-8
https://doi.org/10.5125/jkaoms.2019.45.1.3
Antonio Fabrizio Nifosì (University of Catania)
Mariateresa Zuccarello (University of Catania)
Lorenzo Nifosì (European University of Valencia)
Vanessa Hervas Saus (European University of Valencia)
Gianfilippo Nifosì (Brugmann University Hospital Center)

Abstract

Osteonecrosis of the jaw (ONJ) is a well-known pathological condition in oncology derived from the use of bisphosphonates (BPs) and denosumab. Many molecular and immunological targets have been introduced for daily use in cancer treatment in recent years; consequently, new cases of ONJ have been reported in association with these drugs, especially if administered with BPs and denosumab. When the drugs are administered alone, ONJ is rarely seen. The objective of our study was to analyze the recent literature relative to the association of ONJ with these new drugs highlighting the pathogenic, clinical and therapeutic aspects. The close collaboration between maxillofacial surgeon, oncologist, dentist, and dental hygienist remains the most important aspect for the prevention, prompt recognition, and treatment of this pathology.

keywords
Bone, Infection, Oral manifestations, Immunomodulation, Angiogenesis modulators

Journal of the Korean Association of Oral and Maxillofacial Surgeons